Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease

American Journal of Kidney Diseases

Volumn 38, Issue 4 SUPPL. 1, 2001, Pages

  Quaschning, T ^a   Krane, V ^a   Metzger, T ^a   Wanner, C ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cholesterol; Dyslipidemia; Lipoprotein; Oxidation; Uremia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; DYSLIPIDEMIA; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; OXIDATION; PROTEIN MODIFICATION; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA;

EID: 0034816578     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.27384     Document Type: Conference Paper

References (47)

1. Glomerular macrophages and the mesangial proliferative response in the experimental nephrotic syndrome
2. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis
3. Endothelial function in proteinuric renal disease
4. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure
5. Lipoprotein metabolism and renal failure
6. Progression of renal failure: Role of apolipoprotein B-containing lipoproteins
7. The monitored atherosclerosis regression study (MARS). Design, methods and baseline results
8. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression
9. Triglycerides are more important in atherosclerosis than epidemiology has suggested
10. Intermediate density lipoproteins as an independent risk factor for aortic atherosclerosis in hemodialysis patients
11. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
12. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients
13. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients
14. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men
15. A cholesteryl ester transfer protein gene mutation and vascular disease in dialysis patients
16. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
17. Structural and compositional modifications of diabetic low-density lipoproteins influence their receptormediated uptake by hepatocytes
18. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures
19. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
20. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation
21. Decrease of serum paraoxonase activity in chronic renal failure
22. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients
23. C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD
24. Low-density lipoprotein subclass patterns and risk of myocardial infarction
25. Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients
26. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
27. Small, dense low-density lipoprotein as a risk factor for coronary heart disease
28. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
29. Low density lipoprotein subclasses and risk of coronary heart disease
30. LDL size and risk of coronary heart disease in elderly men and women
31. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men - Prospective results from the Quebec cardiovascular study
32. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease
33. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease
34. Transient changes of serum lipoprotein(a) as an acute phase protein
35. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up
36. Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis?
37. Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension
38. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy
39. Chronic antioxidant use and changes in endothelial dysfunction: A review of clinical investigations
40. Nontraditional cardiovascular disease risk factors in end-stage renal disease: Oxidate stress and hyperhomocysteinemia
41. Glycation and oxidation: A role in the pathogenesis of atherosclerosis
42. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
43. Glyc-oxidized LDL impair endothelial function more potently than oxidized LDL: Role of enhanced oxidative stress
44. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability
45. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: Role of oxidative stress
46. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
47. The CHORUS (cerivastatin in heart outcomes in renal disease: Understanding survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD